Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of EXS73565 administered orally as a single agent in participants with relapsed/refractory B-cell malignancies.
Relapsed or Refractory B-cell Malignancies
DRUG: EXS73565
Number of Participants with Treatment-emergent Adverse Events (TEAEs), Up to 282 days|Dose-limiting toxicities (DLTs) of EXS73565-001, Up to 21 days
Time to Maximum Concentration (Tmax) of EXS73565-001, Up to 253 days|Area Under the Concentration-time Curve from Time Zero to the Time of the Last Quantifiable Concentration AUC(0-last) of EXS73565-001, Up to 253 days|Maximum Concentration (Cmax) of EXS73565-001, Up to 253 days|Overall Response Rate (ORR), Up to 434 days|Disease Control Rate, Up to 434 days|Progression Free Survival, Up to 434 days|Duration of Response, Up to 434 days|Time to Respond, Up to 434 days|Time to Progression, Up to 434 days
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of EXS73565 administered orally as a single agent in participants with relapsed/refractory B-cell malignancies.